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Chronic pain is one of the most burdensome health issues facing the planet
(as costly as diabetes and cancer combined), and in desperate need for new
diagnostic targets leading to better therapies. The bioactive lipid sphingosine
1-phosphate (S1P) and its receptors have recently been shown to modulate
nociceptive signaling at the level of peripheral nociceptors and central neurons.
However, the exact role of S1P generating enzymes, in particular sphingosine
kinase 2 (Sphk2), in nociception remains unknown. We found that both sphingosine
kinases, Sphk1 and Sphk2, were expressed in spinal cord (SC) with higher
levels of Sphk2 mRNA compared to Sphk1. All three Sphk2 mRNA-isoforms were
present with the Sphk2.1 mRNA showing the highest relative expression. Mice
deficient in Sphk2 (Sphk2−/−) showed in contrast to mice deficient in Sphk1
(Sphk1−/−) substantially lower spinal S1P levels compared to wild-type C57BL/6
mice. In the formalin model of acute peripheral inflammatory pain, Sphk2−/− mice
showed facilitation of nociceptive transmission during the late response, whereas
responses to early acute pain, and the number of c-Fos immunoreactive dorsal
horn neurons were not different between Sphk2−/− and wild-type mice. Chronic
peripheral inflammation (CPI) caused a bilateral increase in mechanical sensitivity
in Sphk2−/− mice. Additionally, CPI increased the relative mRNA expression of
P2X4 receptor, brain-derived neurotrophic factor and inducible nitric oxide synthase
in the ipsilateral SC of wild-type but not Sphk2−/− mice. Similarly, Sphk2−/−
mice showed in contrast to wild-type no CPI-dependent increase in areas of
the dorsal horn immunoreactive for the microglia marker Iba-1 and the astrocyte
marker Glial fibrillary acidic protein (GFAP). Our results suggest that the tightly
regulated cell signaling enzyme Sphk2 may be a key component for facilitation of
nociceptive circuits in the CNS leading to central sensitization and pain memory
formation.
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Introduction
Pain, including chronic pain is a major health problem
that greatly reduces the quality of life for the patient and
represents not only a significant social but also economic burden.
Management is poor due to lack of reliable diagnostic tools
to identify specific causes of chronic pain combined with few
and frequently insufficient treatments. Consequently, there is
an urgent unmet medical need for both new diagnostic tools
and better therapies for chronic inflammatory pain. However
this quest is confounded since there are not one but multiple
pathologies and affected signaling pathways that eventually lead
to the chronic inflammatory, neuropathic or pathological pain.
Pain is accompanied by activation of a chain of nociceptive
neurons in dorsal root ganglia (DRG), spinal cord (SC) and the
brain that is modulated by the release of inflammatory mediators
from SC glia as part of tri-partite communication between
microglia, astrocytes and neurons (Liang et al., 2013). The
precise molecular mechanisms regulating this communication
between cells remain an important, but unanswered question.
One molecule that has recently been shown to be involved in
neuronal pain signaling as well as in the function of glia is the
bioactive sphingolipid sphingosine 1-phosphate (S1P; Muscoli
et al., 2010; Mair et al., 2011; Camprubí-Robles et al., 2013;
Finley et al., 2013; Salvemini et al., 2013; Janes et al., 2014).
S1P is generated by the phosphorylation of sphingosine by two
sphingosine kinase isoforms (Sphk1; Sphk2). It can function both
as an extracellular ligand for a family of five G-protein coupled
S1P receptors (S1PR1-5), and as an intracellular messenger
through interactions with and regulation of different cytosolic
and nuclear proteins (for review, see Pitman and Pitson, 2010;
Pitson, 2011). The Sphk1 and Sphk2 proteins differ in size,
intracellular localization and substrate specificity (Bryan et al.,
2008; Liu et al., 2012; Orr Gandy and Obeid, 2013). Sphk1 is a
cytosolic protein that upon activation is phosphorylated by the
Erk1/2 kinases and relocates to the plasma membrane, whereas
Sphk2 is localized to the endoplasmatic reticulum, mitochondria
and has a nuclear localization sequence which allows relocation
into the nucleus (Siow and Wattenberg, 2011; Strub et al., 2011;
Orr Gandy and Obeid, 2013). Interestingly, Sphk2 but not Sphk1
phosphorylates the drug FTY720 (fingolimod, GilenyaTM) into
its active form which has been shown to modulate inflammatory
and neuropathic pain signaling (Coste et al., 2008b; Janes et al.,
2014; Zhang et al., 2015).
Intracerebroventricular injection of S1P produced
antinociceptive effects (Sim-Selley et al., 2009) and acute
and Chronic peripheral inflammation (CPI) reduced the S1P
content in the SC (Coste et al., 2008a). Blockade of spinal S1P1
receptor subtype blocked neuropathic pain (Janes et al., 2014). In
the present study we investigated the impact of Sphk2-deficiency
in acute and chronic inflammatory pain. Based on our novel
findings of changed nocifensive behavior in Sphk2-deficient
mice in response to acute and chronic inflammation we focused
on S1P levels, mRNA and protein expression and level of the
SC dorsal horn as it is an essential area in pain processing and
in the development of central sensitization. Our results indicate
that the tightly regulated cell signaling enzyme, Sphk2, may be
a key component for facilitation of nociceptive circuits in the
CNS eventually leading to central sensitization and pain memory
formation.
Materials and Methods
Animals
Male 6–10 weeks old Sphk1−/− (Allende et al., 2004), Sphk2−/−
(Mizugishi et al., 2005) or C57BL/6 (wild-type, wt) mice (Flinders
Medical Centre Animal house) were used. Mice were housed on
a 12 h light/dark cycle with free access to mouse chow and water.
All procedures were approved by the AnimalWelfare Committee
of the Flinders University.
Formalin-Induced Nocifensive Behavior
For the formalin test (Sun et al., 2013), mice were placed in
plexiglas chambers and left for 15–30 min for acclimatization.
The formalin solutions (0.5 and 2%) were freshly prepared
from 37% formaldehyde solution which equals 100% formalin
(Merck) at the day of injection (Sun et al., 2013). During a short
isoflurane-induced anesthesia 15 µl formalin (2%) solution was
injected into the left plantar hindpaw. 0.5% formalin was injected
subcutaneously into the dorsal hindpaw (Shields et al., 2010).
Injection of sterile saline 0.9% served as control. Subsequently
the mouse behavior was recorded for 45 min. The recordings
were analyzed for the time spent licking, grooming, exploring
or the time without any visible movement. The total amount
of time spent for individual behaviors was separated into 5 min
intervals. The investigator was blinded in respect to the strains
used.
Complete Freund’s Adjuvant (CFA)-Induced
Mechanical Hyperalgesia
Mechanical withdrawal thresholds in response to CPI were
evaluated according to a previously described method (da Costa
et al., 2010). The animals received 20 µl of complete Freund’s
adjuvant (CFA) injected intra plantar in the left hindpaw. The
paw withdrawal behavior was evaluated 1 h before injection
(baseline measure) and at different time-points (4, 24, 48 and
168 h) following CFA injection. Mice (at least one C57BL/6-
wt and one Sphk2-deficient mouse per experiment) were placed
individually in plexiglas container (17.5 × 17.5 × 12 cm) with
four compartments, on an elevated wire mesh platform. The
investigator was blinded with respect to strains used. The animals
were acclimatized for 30 min prior to behavioral testing. The
frequency of withdrawal response (%) was measured following
10 applications of von Frey Hairs onto the plantar surface
of the left and right hindpaw (with a duration of 3–5 s for
each application). Von Frey hairs from 0.0275 to 1.202 g were
used. At days 3 and 7 the thickness of the mid-third of left
(ipsilateral) and right (contralateral) hindpaw was measured
using a caliper. The paw withdrawal threshold of individual mice
was determined at the von Frey hair intensity at which there
was a minimum 50% positive incidences of pain-related behavior
(out of 10 applications of the von Frey hair). In the event that
the von Frey hair did not reach 50%, the next stronger filament
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was used; alternatively, in the event of a positive withdrawal
response, the next weaker stimulus in the series was used. The
paw withdrawal threshold at which mice responded to 50%
of mechanical stimuli prior to and following CFA injection
were used to compare strains and their response to peripheral
inflammation.
Determination of Sphk1 Activity and S1P Content
in Spinal Cord Tissue
Lysis buffer composed of 50 mM Tris/HCl (pH 7.4), 150
mM NaCl, 2 mM activated Na2VO3, 10 mM NaF, 10 mM
β-glycerophosphate, 1 mM EDTA, 1 mM DTT, 10% glycerol,
0.05% Triton X-100 and CompleteTM protease inhibitor
cocktail (Roche) was added to SC tissue in an approximate
1:1 ratio. The tissue was then homogenized with a microtube
pestle (Axygen), followed by 4 × 30 s cycles of sonication
on ice in a Bioruptor bath sonicator (Diagenode, NY, USA).
The lysate was then assayed for Sphk1 activity using D-
erythro-sphingosine and [γ32P]ATP as substrates (Pitman
et al., 2012), and S1P content by high performance liquid
chromoatography with post-column fluroescent derivatization,
as previously described (Leclercq et al., 2011). Protein
concentrations in the lysates were determined using the
Bio-Rad protein assay reagent and bovine serum albumin as
standard.
Isolation of Total RNA and Reverse Transcription
Lumbosacral SC was dissected, ipsi- and contralateral sides
separated and stored in Trizol (Sigma) at −80◦C. Samples
were homogenized using a tissue lyser (Qiagen). Total RNA
was isolated using a column based method (Zymo-Spin ICC
Columns, Zymogen, Irvine, CA, USA). DNA contamination was
removed by on-column DNA digestion. The concentration of
total RNA was determined using standard photospectrometry
(Nanodrop 2000, Thermo Scientific, Australia), quality of
RNA was determined using a lab-on-chip system (Bioanalyser,
Agilent). Only samples with RNA integrity numbers (RIN) above
seven were used for subsequent analysis. One microgram of
total RNA was reverse transcribed into cDNA according to the
manufacturer protocol (SuperscriptII, BioRad, Australia).
qPCR
Quantitative polymerase chain reaction (qPCR) analysis of the
relative mRNA expression levels in the DRG samples was
performed using the StepOnePlus cycler (Life Technologies).
TaqMan primers (Life Technologies) were used for the detection
of pro-inflammatory markers and molecules characteristic for
microglia. Beta-2 microglobulin (B2M) was used as a reference
gene (Vandesompele et al., 2002). The efficiencies of all primer-
pairs were determined by 1/5 to 1/625 dilutions in a qPCR
and a satisfying efficiency was determined with Q-Gene (Simon,
2003). The primers and efficiencies are listed (Table 1). The
final volume for qPCR was 20 µl of which 8 µl were H2O,
10 µl mastermix (Life Technologies), 1 µl assay-mix (Life
Technologies) and 1µl cDNA. Each qPCRwas done in duplicate.
The Ct values were determined for each product and normalized
as pairwise comparisons against the Ct value of the reference
gene. Subsequently the mean normalized expression (MNE) was
calculated and differences in the expression determined (Simon,
2003).
Western Blot
Whole SCs and DRG were lyzed using chilled
radioimmunoprecipitation (RIPA) lysis buffer containing 10
mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% NP-40,
1% Triton X-100, 10% glycerol, 1 mM phenylmethanesulfonyl
fluoride, 1 mM sodium orthovanadate, 1µMbatimastat (BB-94),
and 1% protease inhibitor cocktail (Roche). For Western blots,
lysates were solubilized in an equal volume of 2 × SDS sample
buffer containing 4% SDS, 2% glycine, 0.015% bromophenol
blue, 20% glycerol, and 10% β-mercaptoethanol in 100 mM
Tris-HCl buffer, pH 6.8. Cell lysates were electrophoresed
through 4–12% Bis-Tris buffered SDS gels (Life Sciences).
Proteins were transferred onto poly(vinylidene fluoride) (PVDF)
membrane at 100 V for 1 h. The membranes were blocked
in 4% skim milk powder, 0.1% Tween-20, and 0.02% NaN3
in theta burst stimulation (TBS), pH 8.0, for 1 h at room
temperature and incubated overnight with primary antisera.
The following antibodies were used: rabbit anti-SphK2 (1:500; S
Pitson, Adelaide, SA, Australia) and mouse anti beta-III tubulin
(1:1000; Promega). Membranes were washed three times in
TBS-Tween 20 (TBST), pH 8.0, for 10 min and incubated for
1 h with donkey anti-rabbit horseradish peroxidase (HRP) or
donkey anti-mouse HRP secondary (1:50,000; Invitrogen) in
TBS at room temperature and subsequently washed three times
in TBS for 10 min and developed with Supersignal West Pico
Sensitivity Substrate (Pierce).
Multiple Labeling Immunohistochemistry
For immunohistochemical analysis, animals were euthanized
with an overdose of isoflurane and 20 mm of the lumbosacral
SC covering entry area of the dorsal roots L3-L5 was dissected
and fixed by immersion in Zamboni’s fixative (2% formaldehyde;
0.5% picric acid; 0.2 M sodium phosphate buffer, pH 7.0) at 4◦C
for 24 h. Subsequently, the SC was dehydrated through a graded
series of ethanol and DMSO, embedded in polyethylene glycol
(PEG, 1450 MW: Sigma-Aldrich, St. Louis, MO, USA; Murphy
et al., 1998) and the complete lumbosacral region adjacent to
dorsal roots that connect to the sciatic nerve was sectioned at 12
µm with 10 sections (120 µm) between sections. Free floating
sections were short term stored at 4◦C in PBS-sodium azide or
immediately used for multiple labeling immunohistochemistry.
The sections were blocked with 10% normal donkey serum
in PBS for 30 min and subsequently incubated for 48 h in a
mixture of primary antisera (Table 2), diluted in hypertonic PBS
containing 10% normal donkey serum under humid conditions.
After washing in PBS, sections were incubated for 2 h in a
mixture of secondary antisera (Table 2). After a final PBS wash,
the sections were coverslipped in carbonate-buffered glycerol
(pH 8.6). Microglia was labeled using an antiserum directed
against calcium-binding adapter molecule, Iba-1, astrocytes were
detected using antiserum directed against GFAP, neurons were
labeled with NeuN (Table 2). 4′,6-diamidino-2-phenylindole
(DAPI) was used to stain nuclei.
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 August 2015 | Volume 8 | Article 29
Canlas et al. Sphingosine kinase 2 and spinal nociception
TABLE 1 | TaqMan primer assays.
Primer assay Assay code Amplicon length (bp) Efficiency (R2)
B2M Mm00437762_ml 77 0.9997
Sphkl Mm00448841_gl 65 0.9830
Sphk2 Mm00445021_ml 113 0.9977
Sphk2.1 Mm00445020_ml 133 0.9972
Sphk2.2 Mm00772700_ml 85 0.9959
Sphk2.3 Mm01204085_ml 62 0.9949
P2X4 Mm00501787_ml 66 0.9944
NOS 2 (iNOS) Mm00440502_ml 66 0.9891
Bdnf Mm01334042_ml 108 0.9891
Il-1β Mm00434228_ml 90 0.9997
Il-6 Mm00446190_ml 78 0.9975
The table shows the assay used for qRT-PCR experiments with abbreviations for the mRNAs and mRNA isoforms, assay codes, length of the PCR products in base pairs
(bp) and the tested primer efficiencies.
To investigate the formalin-dependent activation of cells
in the SC dorsal horn we used an antiserum directed
against the proto-oncogene Finkel-Biskis-Jinkins (FBJ) murine
osteosarcoma viral oncogene homolog, c-Fos (Table 2).
Image Analysis
Images of sections with different immunoreactivites were taken
using a BX-50 fluorescence microscope (Olympus, Australia).
Images were imported into ImageJ (NIH, Bethesda, MD, USA)
for subsequent analysis.
The dorsal horn was defined by the characteristic
arrangement and density of DAPI-stained nuclei the area
measured and used for subsequent analyses. Using triple-
labeled images we determined the total number nuclei
(Dapi), of NeuN-positive cells and the areas occupied by
immunoreactivities for Iba-1 or GFAP. The areas and cell
numbers were normalized to 100,000 µm2 to adjust for
differences in measured areas of dorsal horn. Numbers of nuclei
positive for c-Fos in the dorsal horn were counted manually and
each positive c-FOS staining was checked for immunoreactivity
(IR) to the nuclear marker Dapi. Normally 3–4 sections per
animal were used for the analysis of c-Fos IR in response
to acute peripheral inflammation in response to formalin
injection.
For analysis of the CPI13–18 sections with 100µm in between
sections covering the entire lumbosacral entry zone of dorsal
roots L3–5 were analyzed per animal to determine differences
in the immunoreactive areas positive for GFAP and Iba-1. To
correct for differences in staining intensity between animals and
sections, for each section the contralateral side was set as 100%
and IR on the ipsilateral side determined in comparison to the
contralateral side.
Statistical Analysis
For the analysis of relative mRNA expression, responses to
formalin and mechanical hypersensitivity, we used one- or two-
way Analysis of Variance (two-way ANOVA, GraphPad Prism 5,
San Diego, CA, USA). If the resulting F-value was significant
(P < 0.05) for the responses to formalin and mechanical
hypersensitivity, then post hoc t tests with Bonferroni correction
were performed to obtain individual comparisons at each time
point, and significant differences are denoted in figures. For
analysis of immunoreactivities we used paired and unpaired
Students t-test (GraphPad Prism 5). All data are presented as
mean± SEM.
Results
Sphk Expression in Spinal Cord
To determine the presence and relative expression values for
Sphks at the transcriptional level we determined the relative
mRNA expression at different SC levels in C57BL/6-wt mice.
In comparison, the relative mRNA expression levels were
significantly higher for Sphk2 compared to Sphk1 (n = 5,
one-way ANOVA, p < 0.05, Figure 1A) with significantly
higher expression of Sphk2 compared to Sphk1 in thoracic and
lumbosacral SC (n = 5, t-test, p < 0.05). Three Sphk2 mRNA
isoforms are present in mice that differ in their 5′ untranslated
regions, but are translated into identical proteins. Interestingly,
all three Sphk2 mRNAs were significantly differently expressed
TABLE 2 | Primary and secondary antisera.
Primary antisera Source Host animal Dilution Secondary antisera Dilution
GFAP Novacastra Mouse 1:200 Donkey anti mouse IgG FITC conjugated 1:50
Iba-1 AbCam Goat 1:200 Donkey anti sheep IgG Cy5 conjugated 1:50
NeuN Chemicon Mouse 1:200 Donkey anti mouse IgG FITC conjugated 1:50
cFOS Santa Cniz Rabbit 1:600 Donkey anti rabbit IgG Cy3 conjugated 1:100
DAPI Sigma 1:1000
The table shows the used combinations of primary and secondary antisera with dilutions and suppliers.
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(n = 5, one-way ANOVA, p < 0.01) with the Sphk2.1
mRNA transcript showing the highest relative expression
level at cervical, thoracic and lumbosacral levels, followed
by Sphk2.2 and Sphk2.3 (Figure 1B). Analysis of total RNA
from lumbosacral SC showed no difference in relative mRNA
expression levels for Sphk1 between Sphk2−/− and C57BL/6-
wt mice (n = 5, t-test, Figure 1C). Sphk2 mRNA could not be
detected in total RNA extracted from Sphk2−/− mouse tissue
(data not shown).
The presence of the Sphk2 protein in wild-type C57BL/6
SC and DRG and its absence in Sphk2−/− mouse tissue was
confirmed using Western blot (Figure 1D).
The S1P Content in the Spinal Cord is Reduced
but the Sphk1-Activity Unaltered in
Sphk2-Deficient Mice
To investigate Sphk function, we determined the amount of
Sphk2-generated S1P in the SC. To rule out compensatory
mechanisms due to the presence of Sphk1 we analyzed in
addition to S1P content also Sphk1-activity in the SC of
Sphk2−/− and C57BL/6-wt mice (n = 5). The SC of Sphk2−/−
mice contained a significantly lower amount of S1P compared to
C57BL/6-wt mice (paired t-test, p < 0.002, Figure 2B) whereas
the Sphk1-activity was not different between C57BL/6-wt and
Sphk2−/− mice (paired t-test, Figure 2B). This indicates that
Sphk2 is the primary source of S1P in the SC and that there is no
compensatory regulation of Sphk1 in the absence of Sphk2. The
data are supported by the fact that the spinal S1P content was
virtually unchanged in Sphk1−/− mice (Figure 2A). Unchanged
Sphk2 activity in Sphk1−/− has been shown recently (Beroukas
et al., 2015).
Sphk2-Deficiency Modulates the Second but not
First Phase of the Response to Acute
Inflammation
We used the formalin model to investigate differences in the
responses to acute inflammation by determining the 1st and 2nd
phase of the licking response between animals with deficiency
in Sphk2 and C57BL/6-wt. There was a significant difference
in the 2nd phase in response to injection of 2% formalin (two-
way ANOVA, Bonferroni’s post hoc test, n = 8, Figure 3A)
whereas the response to injection of 0.5% formalin was not
different between strains (Figure 3B). Sphk2−/− mice responded
significantly earlier with an increase in time spent licking
(Figure 3A) which was confirmed by comparison of cumulative
licking time from 10–25 min post formalin injection (Figure 3F).
FIGURE 1 | Expression of sphingosine kinases in mouse spinal
cord (SC). Relative mRNA-expression levels as mean normalized
expression (MNE) for (A) the two sphingosine kinase isoform, Sphk1 and
Sphk2, at different levels of the mouse SC. Sphk2 is expressed
significantly higher compared to the Sphk1 isoform in thoracic and
lumbosacral SC levels (n = 5, one-way ANOVA, ∗p < 0.05); (B) the three
Sphk2 mRNA-isoforms at different levels of the mouse SC. The isoforms
were significantly different expressed at all SC levels with Sphk2.1 isoform
showing the highest relative mRNA-expression (n = 5, one-way ANOVA,
Bonferroni’s post hoc test, ∗∗p < 0.01); (C) the Sphk1isoform in SC of
C57BL/6 and Sphk2−/− mice. The relative expression levels were not
different between strains (n = 5, t-test). Values are expressed as mean
± SEM. (D) Western Blot confirmed the absence of the Sphk2 protein in
Sphk2-deficient mice. Sphk2 protein was present in SC and DRG and
could be detected at a molecular weight of about 50 kDa. βIII tubulin
used as reference.
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FIGURE 2 | Sphingosine kinase activity and sphingosine 1-phosphate
(S1P) levels in mouse SC. (A) Assessment of the amount of spinal S1P in
C57BL/6 and Sphk-deficient mice. Whereas the amount of S1P was
substantially reduced in SCs from Sphk2−/− mice in comparison to C57BL/6
it was virtually unchanged in Sphk1−/− mice (n = 5, one-way ANOVA,
Bonferroni’s post hoc test, ∗∗∗p < 0.001). (B) The Sphk1 activity was not
different between SCs of C57BL/6 and Sphk2−/− mice (n = 5, paired t-test).
But C57BL/6-wt mice spent significant more time licking from
25–45 min (Figure 3F) and overall more time (Figure 3C,
unpaired t-test, p < 0.05). The time course of the 1st phase
of licking response was not different between strains and the
overall time spent licking within the first 10min was not different
(Figures 3A,D).
Acute Peripheral Inflammation Increases
Immunoreactivity for the Astrocyte Marker GFAP
in the Ipsilateral Dorsal Horn of Sphk2−/− and
Wild-type C57BL/6 Mice
We considered that the behavioral differences might have
been related to differences in the cellular composition of
the dorsal horn. To investigate differences in the cellular
composition related to Sphk2-deficiency, we used multiple
labeling immunohistochemistry to compare overall cell number,
number of neurons and presence of astrocytes and microglia. We
compared the number of DAPI-positive nuclei, the number of
NeuN-positive cells and areas occupied by IR for GFAP or Iba-1
and in the SC dorsal horn between strains in response to saline,
formalin and in mice without treatment. The total number of
DAPI-positive nuclei, NeuN-immunoreactive neurons and areas
with IR for Iba-1 were not different between strains in absence
of treatment (Figure 4A) and did not change in the response
to treatment (Figures 4B,D). This indicates no loss of neurons
or microglia in Sphk2-deficient adult SC. Surprisingly, in both
strains a larger area of the dorsal horn was occupied by clear
GFAP-IR on the ipsilateral compared to the contralateral side
60 min after injection of 2% formalin (n = 10, t-test, p < 0.05,
Figure 4C).
FIGURE 3 | Licking response to acute peripheral inflammation induced
by formalin. (A) Time course of the response of C57BL/6 mice (black
squares) and Sphk2−/− mice (black circles) to injection of 2% formalin. Time
points represent mean ± SEM response of eight animals during 5 min
intervals. Asterisks indicate significantly greater time licking (*p < 0.05,
two-way ANOVA, Bonferroni’s test). (B) Time course of the response of
C57BL/6 mice (black squares) and Sphk2−/− mice (black circles) to injection
of 0.5% formalin. The response to injection of 0.5% formalin was not different
between strains. (C–F) Cumulative paw licking time in intervals. Values
represent mean ± SEM. (C) Overall time spent licking in response to 2%
formalin (unpaired t-test, *p < 0.05). (D) Overall response to 0.5% formalin. (E)
Time spent licking between 10–25 min (unpaired t-test, *p < 0.05). (F) Time
spent licking between 25–45 min (unpaired t-test, *p < 0.05).
Acute Peripheral Inflammation Increases the
Number of c-Fos Positive Neurons
To investigate if the behavioral differences are related to
difference in the activation of dorsal horn neurons, we
determined the number of c-FOS positive neurons in the SC
dorsal horn. Injection of 2 and 0.5% formalin into the left
hindpaw increased the number of nuclei with IR for c-Fos
in the lumbar SC of both strains. The IR was present in
laminae I and II and in a small number of nuclei in deeper
lamiae and was restricted to NeuN–immunoreactive neurons
(Figures 5A,B). The number of c-Fos immunoreactive neurons
increased significantly on the ipsilateral side in response to
acute peripheral inflammation induced by 2 and 0.5% formalin
(n = 5, one-way ANOVA, Figure 5). However, untreated or saline
injected mice, stained only occasionally for c-Fos positive nuclei
were present in the dorsal horn (Figures 5E,F). The increase and
number of c-Fos positive neurons was not significantly different
between strains.
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FIGURE 4 | Microglia and astrocytes in the dorsal horn in C57BL/6 and
Sphk2−/− mice. (A) Areas with immunoreactivity (IR) for the astrocyte marker
GFAP and the microglia marker Iba-1 in the dorsal horn of untreated C57BL/6
and Sphk2−/− mouse SC normalized to 100,000 µm2 (n = 5, unpaired t-test,
n.s.). (B) Area with IR for Iba-1 in the dorsal horn of C57BL/6 and Sphk2−/−
mouse SC 60 min post injection of two percent formalin, normalized to 100,000
µm2 (n = 10, unpaired t-test, n.s.). (C) Area with IR for GFAP in C57BL/6 and
Sphk2−/− mouse SC dorsal horn 60 min post injection of two percent formalin,
normalized to 100,000 µm2 (n = 10, unpaired t-test, *p < 0.05). (D) Number of
nuclei immunoreactive for NeuN in C57BL/6 and Sphk2−/− mouse SC dorsal
horn 60 min post injection of two percent formalin, normalized to 100,000 µm2
(n = 10, unpaired t-test).
Sphk2-Deficiency Increases Mechanical
Sensitivity in Response to Chronic Inflammation
in the ipsi- and Contralateral Hindpaw
The observed nocifensive behavior differences in response to
acute inflammation suggested that absence of Sphk2 changes the
nociceptive processing at the level of the SC. To examine the
effects of Sphk2-deficiency on the response to CPI we analyzed
the behavior in response to mechanical stimulation. There was
no significant difference in paw withdrawal threshold between
the ipsilateral and contralateral hind paws prior to CFA injection
(Figure 6A). The injection of CFA in hindpaws of C57BL/6
mice caused a persistent significant reduction of the mean paw
withdrawal threshold ipsilateral to the injection site starting
after 4 h and still present on day 7 (n = 8, two-way ANOVA,
Bonferroni’s post hoc test, p < 0.05, Figure 6A). A significant
interaction was present between affected site and measurement
(two-way ANOVA, p< 0.0001).
Mice with deficiency in Sphk2 showed a similar reduction
in mechanical threshold of the ipsilateral hind paw in response
to CFA (n = 9, two-way ANOVA, Bonferroni’s post hoc
test, p < 0.0001, Figure 6A) compared to baseline before
injection. Surprisingly, the contralateral side showed also a
strong reduction in mechanical threshold that was not different
from the ipsilateral side but was significantly different from
the contralateral side in C57BL/6-wt animals (n = 8, two-way
ANOVA, Bonferroni’s post hoc test p< 0.0001, Figure 6A).
Analysis of the paw oedema showed no differences between
C57BL/6-wt- and Sphk2−/− mice (Figure 6B). The ipsilateral
paws showed similar increase in thickness of the mid-hindpaw
in response to saline and CFA injection after 3 and 7 days (n =
7–10 per condition and strain) and daily observation showed no
differences in the behavior or the extent of inflammation.
S1P Levels in Spinal Cord in Response to
Chronic Inflammation
As these behavioral differences and the presence of bilateral
hypersensitivity might be reflected by differences at the level
of S1P synthesis, we analyzed the S1P content in ipsi- and
contralateral SC in mice 7 days after a CFA injection into the
left hindpaw. No differences were observed between ipsi- and
contralateral S1P content (n = 4) in both strains. However similar
to non-inflamed mice, Sphk2−/− mice had significantly lower
SC S1P levels compared to C57BL/6 mice (Figure 7, one-way
ANOVA, Bonferroni’s post hoc test, p< 0.0001).
Sphk2-Deficiency Reduces Spinal mRNA
Expression of P2X4, Bdnf and Nos2 in Response
to Chronic Inflammation
To determine whether nocifensive behavior differences could be
related to changes in the signaling response to inflammation,
we analyzed the expression of molecular markers involved in
the spinal response to peripheral inflammation. The responses
to inflammation in the periphery changed the expression of
marker molecules at the level of the SC but not the relative
expression levels for Sphk1. The Sphk1 mRNA-expression in
the lumbosacral SC did not change in Sphk2-deficient mice 7
days after CFA injection (Figure 8) whereas injection of CFA
into the left hindpaw induced a significant increase in mRNA
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FIGURE 5 | IR for c-Fos in the dorsal horn of C57BL/6 and Sphk2−/−
mice in response to acute peripheral inflammation. (A,B) Double-
labeling immunohistochemistry for NeuN and c-Fos. Nuclei with
immuno-reactivity for NeuN (A) and c-Fos (B) in the ipsilateral SC dorsal horn
after injection of formalin into the hindpaw. c-Fos positive nuclei also showed
IR for NeuN. The arrows indicate some double-labeled nuclei. The asterisk
indicates background labeling of capillaries. Bar = 50 µm. (C) Number of
nuclei with IR for c-Fos in the SC dorsal horn of C57BL/6 and Sphk2−/− mice
60 min after injection of two percent formalin. (D) Number of nuclei with IR for
c-Fos in the SC dorsal horn of C57BL/6 and Sphk2−/− mice 60 min after
injection of 0.5% formalin. (E) Number of nuclei with IR for c-Fos in the SC
dorsal horn of C57BL/6 and Sphk2−/− mice 60 min after injection of saline.
(F) Number of nuclei with IR for c-Fos in the SC dorsal horn of C57BL/6 and
Sphk2−/− mice in untreated SC. Values represent mean ± SEM, n = 5,
one-way ANOVA, Bonferroni’s post hoc test, *p < 0.05.
expression for P2X4 receptors, Bdnf and Nos2 (iNOS) in the
ipsilateral SC of C57BL/6-wt mice compared to the ipsilateral
SC of Sphk2-deficient mice Those changes in relative mRNA
expression levels were absent in the SC of Sphk2-deficient
mice (n = 6–9, one-way ANOVA, Bonferroni’s post hoc test,
Figure 8). Relative expression levels of the interleukins IL-
1β and IL-6 were not significantly different between strains
(Figure 8).
Sphk2-Deficiency Increases Iba-1 Positive Area
in Response to Chronic Inflammation in the ipsi-
and Contralateral Lumbosacral Dorsal Horn
Positive labeling for astrocytes (GFAP) and microglia (Iba-1)
could be observed throughout the SC dorsal horn. The SC
of untreated control animals and animals injected with saline
showed no difference of Iba-1 staining between ipsi- and
FIGURE 6 | Paw withdrawal thresholds in response to chronic
peripheral inflammation (CPI) induced by CFA in C57BL/6 and
Sphk2−/− mice. (A) Time course of paw withdrawal thresholds in response
to intraplantar injection of CFA in C57BL/6 (n = 8, ipsilateral, upwards pointing
triangles solid line; contralateral downward pointing triangles solid line) and
Sphk2−/− (n = 8, ipsilateral, circles dashed line; contralateral squares dashed
line) hindpaws (two-way ANOVA, Bonferroni’s post hoc test, *p < 0.05).
(B) Difference in mid-hindpaw thickness of the between ipsi- and contralateral
side in response to CFA injection. Values represent mean ± SEM.
contralateral sides and between C57BL/6-wt and Sphk2−/−
mice (Figure 9). Sections of C57BL/6-wt mice showed 7 days
post CFA injection significant increases in areas with IR for
GFAP and Iba-1 in ipsilateral lumbosacral SC dorsal horn
(Figure 9, one-way ANOVA, Bonferroni’s post hoc test, 60–80
sections, n = 5). This increase was absent in Sphk2−/− mice
(Figure 9). The increase was reflected by overall increased
IR ipsilateral compared to contralateral over the entire length
of lumbosacral SC. However, immunoreactivities varied in
between different segments along the lumbosacral SC with
differences of up to 60% between sections in all animals.
The total number of nuclei in the dorsal horn was not
different between ipsi- and contralateral sides, strains and
treatment.
Discussion
Our study has shown that activation of the Sphk2 isoform
is part of nociceptive signaling in response to acute and CPI
at the level of the SC. We demonstrated for the first time
that Sphk2-deficient mice respond earlier but with decreased
intensity to acute inflammation and develop bilateral mechanical
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FIGURE 7 | S1P content of ipsi- and contralateral SC in response to
CPI induced by CFA in C57BL/6 and Sphk2−/− mice. Analysis of the
amount of S1P in C57BL/6 and Sphk-deficient mice at 7 days post-CFA
injection into the hindpaw. The amount of S1P was substantially reduced in
ispi- and contralateral SCs from C57BL/6 and Sphk2−/− mice in comparison
to untreated controls (control, n = 5, ispi- and contralateral SC n = 4, one-way
ANOVA, Bonferroni’s post hoc test, ∗∗∗p < 0.001).
hypersensitivity in response to chronic inflammation. The
behavioral changes to CPI were accompanied by the novel
finding of a bilateral reduction in spinal S1P levels. Sphk2-
deficient mice also failed to respond to CPI at the level
of activation of glia and increased expression of glia-related
mRNAs.
Studies in gene-deficient mice have been shown to generate
fundamental insight in the signaling pathways underlying
chronic and neuropathic pain. Unfortunately knock-out of a
gene can cause compensatory upregulation of other related
genes. Deletion of Sphk2−/− has been shown to induce Sphk1
in the circulation (Kharel et al., 2012; Liang et al., 2013).
To determine the impact of Sphk1 on the S1P content in
the mouse SC and to rule out a compensatory regulation
of Sphk1 in Sphk2−/− mice we measured S1P levels, Sphk
activities and relative mRNA expression levels for the Sphk
isoforms. Although Sphk1 activity was not different between
Sphk2−/− and C57BL/6-wt SC, the absence of Sphk2 but not
Sphk1 strikingly reduced S1P levels. This suggests an absence
of a compensatory mechanism in the regulation of Sphk1 and
supports the notion that the Sphk2 isoform is the predominant
source of S1P in the SC. Our results are corroborated by recent
studies using a different Sphk2-deficient mouse strain where a
similar reduction in spinal S1P levels was shown (Zhang et al.,
2015).
The Sphk2 isoform being the predominant Sphk in the SC
is significant, as recent evidence indicates it may play a critical
role in nociceptive signaling. Mice with genetic ablation of Sphk2
but not Sphk1 showed signs of thermal hyperalgesia in response
to Zymosan injection (Coste et al., 2008a). Our study suggests
the involvement of Sphk2 activation in the processing of acute
inflammation but not acute pain. Whereas the acute response to
injection of formalin and subsequent activation of sensory fibers
in the skin (1st phase) was identical in C57BL/6 and Sphk2−/−
mice, this was not the case for the 2nd phase. Absence of Sphk2
caused a significantly earlier response peak (Figure 3). The 2nd
phase of the formalin test is thought to be related to central
sensitization (Hunskaar and Hole, 1987; Yaksh et al., 2001) at
the level of the SC indicating a role of Sphk2-generated S1P at
the level of SC and/or higher brain centers although a recent
publication questions it and relates both phases to the activity of
DRG neurons (Fischer et al., 2014). These differences in response
to acute inflammation between Sphk2−/− and C57BL/6 mice are
not based on a difference in the basal sensitivity to mechanical
stimuli since the response to lower formalin concentration and
the initial response to 2% formalin were similar between strains.
These behavioral changes were not accompanied
by differences in IR for glial markers or NeuN. Our
immunohistochemical analysis of the overall number of
cells, of neurons and of GFAP-positive astrocytes and Iba-1
positive microglia in the dorsal horn also suggests that deficiency
in Sphk2 does not lead to loss of neurons or glia. The absence
of changes in microglia reflected by Iba-1 IR in response to 1 h
acute inflammation is in line with experiments that showed
activation of microglia in response to formalin was not present
within the first hour and started at later time points post injection
(Lin et al., 2007).
Since mechanical hypersensitivity in response to chronic
inflammation is likely to be mediated via changes in pain
processing at the level of the SC (see review Latremoliere
and Woolf, 2009) we used the CFA model of CPI to further
investigate the role of Sphk2 at the SC level.
Our observation of bilateral mechanical hypersensitivity
i.e., enhanced hypersensitivity not only in the ipsilateral but
also contralateral hindpaw of Sphk2-deficient mice suggests
that Sphk2 is involved in the communication between ipsi-
and contralateral side of the SC dorsal horn. We found no
differences in oedema size over time and no difference in the
extent of inflammation or ipsilateral PWL between C57BL/6
and Sphk2−/− mice which indicates no obvious difference at
the level of the inflammation in the skin and the response
to peripheral chronic inflammation at the level of primary
nociceptive neurons. Similarly Linke et al. (2012) found no
differences in the response to Zymosan in Sphk2-deficient
mice in the first 48 h but did not report on contralateral
effects. Contralateral pain is still not well understood. Acute
pain is usually well mapped to the site of peripheral injury
or inflammation. However, in wide-spread chronic pain, pain
and mechanical allodynia (pain perception upon non-noxious
mechanical stimulation) is experienced on unaffected sites
of the body even contralateral to the injured or inflamed
side. Contralateral allodynia usually has a delayed onset and
is usually weaker compared to pain on the ipsilateral side
(Milligan et al., 2003; Chang and Waxman, 2010) and is
regularly observed in different animal models of neuropathic
and inflammatory pain including burn injury (Leclercq et al.,
2011), ligation and inflammation of the sciatic nerve, or
peripheral inflammation after injection of carrageenan or CFA
(Milligan et al., 2003; Schreiber et al., 2008; Gao et al.,
2010). Since peripheral nociceptors on the contralateral side
are neither stimulated nor damaged, it is unlikely that they
be the primary source of contralateral allodynia. In our
experiments the initial response to injecting formalin injection
and the mechanical sensitivity before CFA injection were not
different between C57BL/6 and Sphk2−/− mice. This indicates
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FIGURE 8 | Relative mRNA expression in ipsi- and contralateral SC
in response to CPI. Relative mRNA expression levels in the SC of
C57BL/6 mice and Sphk2-deficient mice (Sphk2−/−). The data are
presented as MNE. (A) Relative mRNA-expression levels for sphingosine
kinase 1 (Sphk1) in ipsi- and contralateral lumbosacral SC of C57BL/6 and
Sphk2−/− mice after 7 days CFA. (B) Relative mRNA-expression levels for
the P2X4 receptor (P2X4) in lumbosacral SC of untreated control mice
(control) and in ipsi- (ipsi) and contralateral (contra) lumbosacral SC of
C57BL/6 and Sphk2−/− mice after 7 days CFA. (C) Relative
mRNA-expression levels for the Bdnf in lumbosacral SC of untreated
control mice (control) and in ipsi- (ipsi) and contralateral (contra)
lumbosacral SC of C57BL/6 and Sphk2−/− mice after 7 days CFA.
(D) Relative mRNA-expression levels for the Nos2 (iNos) in lumbosacral SC
of untreated control mice (control) and in ipsi- (ipsi) and contralateral
(contra) lumbosacral SC of C57BL/6 and Sphk2−/− mice after 7 days CFA.
(E,F) Relative mRNA-expression levels for the Il-1β and Il-6 in lumbosacral
SC of untreated control mice (control) and in ipsi- (ipsi) and contralateral
(contra) lumbosacral SC of C57BL/6 and Sphk2−/− mice after 7 days CFA.
Values represent mean ± SEM, n = 5–8, one-way ANOVA, Bonferroni post
hoc test, ∗p < 0.05, ∗∗p < 0.01.
that peripheral nociceptors are unlikely responsible for the
contralateral hypersensitivity. Previous studies using Sphk-
deficient mice showed that mice with deficiency for Sphk2 but
not Sphk1 showed significant lower pain thresholds to heat
(Coste et al., 2008b). However, the study did not investigate
mechanical thresholds and did not comment on bilateral
effects.
Interestingly Sphk2−/− SC contained significantly reduced
S1P levels which confirms a recently published study (Zhang
et al., 2015). However we could show that under chronic
inflammatory conditions S1P-levels drop in C57BL/6 SC to levels
of Sphk2-deficient mice. A reduction of spinal S1P levels had
been shown in response to formalin and carrageenan but only
investigated the response up to the first 9 h (Coste et al., 2008a).
Here we show for the first time bilateral S1P reduction under
chronic inflammatory conditions and provide indirect evidence
that suggest the inhibition of mainly Sphk2 as the reason for
reduced S1P levels. Nevertheless an involvement of Sphk1 cannot
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FIGURE 9 | Microglia and astrocytes in the dorsal horn in C57BL/6 and
Sphk2−/− mice in response to chronic inflammation. Areas of the ipsi-
and contralateral (contra) SC dorsal horn with IR for GFAP (A,C), Iba-1 (B,D)
and positive staining for Dapi (E) in C57BL/6 (A,B,E) and Sphk2−/− (C, D)
lumbosacral SC 7 days post injection of CFA (CFA) or saline (saline) into the
left hindpaw. Values represent mean ± SEM, n = 5, one-way ANOVA,
Bonferroni’s post hoc test, ∗p < 0.05, ∗∗∗p < 0.001.
be ruled out since S1P levels also dropped in Sphk2-deficient
mice.
Recent results suggest that in addition to neurons, microglia
might also be involved in the development of contralateral
hypersensitivity (Choi et al., 2015). The study identified that
inhibition of astrocyte activation via microglia prevents bilateral
hypersensitivity in response to peripheral inflammation. The
involvement of microglia in the process is intriguing. In our
study we found that the increase in mRNAs for several markers
that are characteristic for activated microglia in response to
peripheral inflammation was absent in mice with deficiency in
Sphk2.
One of those markers is the ATP-receptor subtype P2X4.
The generation and presence of P2X4 receptors in microglia
is important for the development of mechanical allodynia and
they are upregulated in microglia in response to peripheral
inflammation (Tsuda et al., 2003). This upregulation is important
for subsequent Bdnf production and release from microglia
as it has been shown in response to peripheral nerve injury
(Ulmann et al., 2008). Synthesis and release of Bdnf from spinal
microglia causes the disinhibition of GABAergic interneurons
(Trang et al., 2012). The connection of P2X4 and Bdnf
is supported in our study at the transcriptional level. Our
studies showed absence of increases in P2X4 and Bdnf in
Sphk2−/− SC. This furthermore indicates a prominent role
of Sphk2 activation and S1P in those signaling pathways and
also suggests the involvement of microglia. We also found
absence of an increase in relative mRNA expression for the
NOS2 isoform, iNOS. Microglia express iNOS (Sung et al.,
2012) and iNOS is increased in response to inflammation
but there seems to be no direct impact of iNOS on the
response to CFA since complete knock-out of iNOS had no
effect on mechanical hypersensitivity in response to peripheral
inflammation (Boettger et al., 2007). The increase in iNOS
mRNA might be related to signaling from higher brain centers.
Reduction of µ-opiod receptor expressing cells in the medulla
reduced the expression of iNOS in the dorsal horn of rats in
response to CFA injection (Carr et al., 2014). In our study,
absence of the peripheral inflammation-dependent increase
in mRNA expression for molecules that are predominantly
expressed in microglia was accompanied by absence of increased
IR for the marker of microglia Iba-1. Based on the findings one
hypothesis is, that S1P, generated from Sphk2 in SC microglia
is part of the signaling that leads to activation of microglia
and Sphk2 and microglia are involved in the communication
between ipsi- and contralateral SC. The process of S1P-
mediated activation of microglia with subsequent synthesis of
pro-inflammatory mediators has been shown in experiments
conducted to demonstrate the connection between chronic
morphine administration and S1P signaling in rats (Muscoli
et al., 2010).
Thus, our data strongly support the notion that the Sphk2
isoform is a key molecule involved in pain processing at the
level of the SC dorsal horn. Furthermore, our data suggest a
direct or indirect involvement of Sphk2 function in the glial
response to peripheral inflammation, as well as in the inhibition
of contralateral allodynia.
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